ArticleFrontiers in oncology2022

Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation.

Yajie Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.